Hepatitis B surface antigen 0.6 take entecavir to turn negative chance is very small, most patients long-term use of this drug can not do hepatitis B surface antigen to turn negative. Entecavir belongs to nucleoside antiviral drugs, the principle of its treatment of hepatitis B virus is to inhibit the replication of the hepatitis B virus so as to achieve the effect of anti-virus, but the complete elimination of the virus, the surface antigen of the chance of turning negative, most patients in the use of the drug after the surface antigen of hepatitis B is still unable to turn negative. However, there are also patients who can turn the surface antigen negative after long-term use of entecavir, but the probability of this happening is very low. Patients with hepatitis B surface antigen 0.6 and abnormal liver function or histologic damage to the liver need to take entecavir antiviral therapy, which can not only effectively inhibit viral replication, but also reduce the incidence of cirrhosis and liver cancer caused by hepatitis B. The drug should be used in accordance with the instructions of the patient. Hepatitis B treatment should be used in accordance with the doctor’s instructions to avoid adverse consequences.